ZHI is now offering to all global manufacturers interested in becoming a licensee, its patented technology for the quantitative and proven transdermal delivery of CBD.
We’re excited about our new flagship product, The ZT Patch™, designed to deliver 21.2mg of hemp-derived CBD. We have validated all data with Kaycha Labs, an independent testing laboratory.”
— Robert Galler, president
LAKE WORTH, FLORIDA, USA, August 17, 2022 /EINPresswire.com/ — Transdermal technology offers an easy-to-use method of delivering a steady, consistent dose of an active ingredient. The transdermal delivery methodology provides unmatched safety and control, allowing product use to be discontinued at any time, making accidental overdose nearly impossible.
Robert C. Galler, chairman and president of ZHI, stated, “We are thrilled with our new flagship product, The ZT Patch™, designed to deliver 21.2 mg of CBD from hemp. We have validated the performance with Kaycha Labs, an independent testing laboratory. The results of a bioavailability study determined that volunteers who wore the ZT Patch ™ for 24 hours showed almost complete delivery of the directly targeted dose to the body. All ZT Patches™ maintained effective adhesion throughout the duration of the test. Galler continued, “We are very excited about our patented technology and believe it will make the industry much safer by providing better predictive results for all users. This is a breakthrough for people who want to get the benefits of CBD without uneven effects due to fluctuating dosage ZHI products are designed to deliver precise amounts of CBD continuously for 24 hours and our ZT Patch™ has a state-of-the-art adhesive that can even be worn in the shower, while swimming and during all physical activities; Dosing is continuous while wearing the ZT Patch™ and can be stopped at any time by simply removing it. We look forward to launching the ZHI brand of controlled-release CBD products and working with our licensees to continue the effectiveness of user outcomes.”
Many other companies have attempted to develop effective transdermal patches for CBD delivery; ZHI believes this is the first transdermal patch to show effective delivery and wear. ZHI’s proprietary manufacturing process meets exacting quality and consistency standards, and ZT Patches™ are individually wrapped and shelf stable. ZHI is applying for patent protection and has extensive knowledge for small and large scale manufacturing. The company offers its technology for licensing or custom manufacturing.
Based in South Florida, ZHI provides licensing opportunities to the legal bioactive industry. The company offers regulatory and operational expertise, tracking and anti-counterfeiting options, manufacturing, packaging and product development.
Robert Galler
ZHI Florida
+1 561-295-8888
Email us here
You just read:
News provided by
August 17, 2022, 09:00 GMT
EIN Presswire’s priority is source transparency. We don’t allow opaque clients, and our editors try to be careful to remove fake and misleading content. As a user, if you see something we’ve missed, please let us know. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™, tries to define some of the limits that are reasonable in today’s world. See our editorial guidelines for more information.